5 ms·

This is really interesting. Obviously evidence in mice is a long way away from demonstrated safety & efficacy in humans but I'll be curious to see where this on

This is really interesting. Obviously evidence in mice is a long way away from demonstrated safety & efficacy in humans but I'll be curious to see where this one goes. If non-healthcare-professionals could be trained to administer a nasal vaccine (the way many non-hcps are able to carry and administer nasal naloxone in case of opiate overdose), it seems like it might potentially make vaccine adoption faster or more widespread.

InInteraction 6y ago
They evaluated "the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor" https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0 https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0
- keeganpoppen 6y ago
  what the hell? that is quite odd, considering they have quotes from a professor at the university in the press release talking about mice as well... and it's not as though the press release is old or anything. shrug
- jashephe 6y ago
  Just to clarify — the vaccine uses as its backbone a type of adenovirus that typically infects chimpanzees, modified by the addition of pieces from SARS-CoV-2, but the experiments testing efficacy are performed in mice (specifically, a type of mice engineered to express humanized ACE2). This vaccine has not been tested in chimpanzees (and actually such experiments would probably be a challenge, since they may have existing immunity to the backbone adenovirus). (edit: parent comment initially mentioned experiments in chimpanzees rather than mice)
abeppu 6y ago
Are there broader frameworks for considering the risks/benefits of training/encouraging non-healthcare-providers to administer healthcare interventions? In something like administering naloxone or I suppose CPR training, or even just educating people about the Heimlich Maneuver, it seems like a key contributor is that an immediate response by someone on the scene of an emergency is critical. The expectation is "if you happen to encounter such an emergency, you're now able to do something to help". What you're suggesting seems qualitatively different -- proactively sending out non-healthcare-providers to administer something to people before they get sick. And yet, if we want to administer it to billions of people quickly, maybe that will be necessary. I also wonder if that will be the bottleneck, or if producing/distributing everywhere it will be.

InInteraction 6y ago

They evaluated "the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor" https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0 https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0

keeganpoppen 6y ago
what the hell? that is quite odd, considering they have quotes from a professor at the university in the press release talking about mice as well... and it's not as though the press release is old or anything. shrug
jashephe 6y ago
Just to clarify — the vaccine uses as its backbone a type of adenovirus that typically infects chimpanzees, modified by the addition of pieces from SARS-CoV-2, but the experiments testing efficacy are performed in mice (specifically, a type of mice engineered to express humanized ACE2). This vaccine has not been tested in chimpanzees (and actually such experiments would probably be a challenge, since they may have existing immunity to the backbone adenovirus). (edit: parent comment initially mentioned experiments in chimpanzees rather than mice)

abeppu 6y ago

Are there broader frameworks for considering the risks/benefits of training/encouraging non-healthcare-providers to administer healthcare interventions? In something like administering naloxone or I suppose CPR training, or even just educating people about the Heimlich Maneuver, it seems like a key contributor is that an immediate response by someone on the scene of an emergency is critical. The expectation is "if you happen to encounter such an emergency, you're now able to do something to help". What you're suggesting seems qualitatively different -- proactively sending out non-healthcare-providers to administer something to people before they get sick. And yet, if we want to administer it to billions of people quickly, maybe that will be necessary. I also wonder if that will be the bottleneck, or if producing/distributing everywhere it will be.